Vira Therapeutics

ViraTherapeutics Develops Highly Effective Cancer Treatments Based on Oncolytic (Cancer-Destroying) Viruses. The company's proprietary oncolytic virus, VSV-GP, efficiently destroys cancer cells while leaving normal tissues unharmed. ViraTherapeutics is currently conducting preclinical safety and efficacy studies for VSV-GP, with the aim of initiating the first clinical trials in cancer patients.